Want to see AU:4DX full AI Analyst Report?
Top Page
4DMedical Ltd
(Sydney:4DX)
Select Model
Select Model
Rating:45Neutral
Price Target:
AU$4.00
â–Ľ(-31.51% Downside)
Action:Reiterated
Date:06/20/26
The score is held back primarily by weak financial performance (declining revenue, persistent losses, and negative cash flows). Technicals provide partial support with price above key moving averages, but momentum signals are mixed. Valuation remains constrained by negative earnings and no provided dividend yield.
Positive Factors
Proprietary XV imaging platform
4DMedical's XV platform is a differentiated, clinically focused imaging and analytics product that produces functional lung maps used in diagnosis, treatment planning and monitoring. That specialized tech and clinical channel focus support durable demand from hospitals and respiratory care providers.
Negative Factors
Declining revenue trend
A sustained revenue decline erodes scale benefits and makes it harder to absorb fixed R&D and commercialization costs. Over a multi-month horizon this constrains ability to build recurring revenues and delays breakeven on investments in clinical adoption and sales capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary XV imaging platform
4DMedical's XV platform is a differentiated, clinically focused imaging and analytics product that produces functional lung maps used in diagnosis, treatment planning and monitoring. That specialized tech and clinical channel focus support durable demand from hospitals and respiratory care providers.
Read all positive factors
4DMedical Ltd (4DX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$2.38B
Dividend YieldN/A
Average Volume (3M)10.77M
Price to Earnings (P/E)―
Beta (1Y)2.20
Revenue Growth-0.80%
EPS Growth-249.48%
CountryAU
Employees124
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.32
Shares Outstanding599,638,850
10 Day Avg. Volume5,850,211
30 Day Avg. Volume10,774,582
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.80
Price to Sales (P/S)8.81
P/FCF Ratio-1.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$4.97Price Target Upside-14.95% Downside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.06
Revenue Forecast (FY)AU$22.27M
4DMedical Ltd Business Overview & Revenue Model
Company Description
Incorporated in 2012 and headquartered in Carlton, Australia, 4DMedical Limited operates as a medical technology enterprise across Australia and the United States. The company primarily focuses on bringing to market its innovative XV Technology, a...
How the Company Makes Money
null...
4DMedical Ltd Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
45
Neutral
Cash Flow
35
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.33M | 5.85M | 3.75M | 718.58K | 1.05M | 216.98K |
| Gross Profit | -17.18M | 5.39M | 3.52M | 684.43K | 280.62K | 125.13K |
| EBITDA | -35.46M | -45.82M | -31.86M | -33.74M | -35.25M | -18.04M |
| Net Income | -159.59M | -30.07M | -35.98M | -31.46M | -24.59M | -21.42M |
Balance Sheet | ||||||
| Total Assets | 139.55M | 94.81M | 120.02M | 92.92M | 74.31M | 92.64M |
| Cash, Cash Equivalents and Short-Term Investments | 56.76M | 6.88M | 30.61M | 69.58M | 51.11M | 80.88M |
| Total Debt | 6.42M | 4.31M | 5.12M | 5.14M | 6.24M | 1.69M |
| Total Liabilities | 167.95M | 30.58M | 49.09M | 21.46M | 14.80M | 9.28M |
| Stockholders Equity | -28.40M | 64.24M | 70.93M | 71.46M | 59.51M | 83.36M |
Cash Flow | ||||||
| Free Cash Flow | -22.99M | -34.56M | -31.17M | -23.38M | -28.35M | -15.25M |
| Operating Cash Flow | -22.82M | -34.48M | -30.87M | -22.65M | -25.27M | -14.52M |
| Investing Cash Flow | -1.62M | -1.62M | -40.04M | -1.61M | -3.50M | -580.45K |
| Financing Cash Flow | 75.41M | 12.37M | 31.94M | 42.73M | -995.47K | 87.55M |
4DMedical Ltd Technical Analysis
Neutral
5.84
Price Trends
3.91
Positive
4.40
Negative
3.55
Positive
Market Momentum
-0.01
Positive
44.67
Neutral
16.35
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:4DX, the sentiment is Neutral. The current price of 5.84 is above the 20-day moving average (MA) of 4.27, above the 50-day MA of 3.91, and above the 200-day MA of 3.55, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 44.67 is Neutral, neither overbought nor oversold. The STOCH value of 16.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:4DX.
4DMedical Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | AU$41.21B | 18.59 | 24.41% | 0.95% | 8.62% | 14.49% | |
55 Neutral | AU$102.97M | -38.02 | -5.31% | ― | 18.21% | 65.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$2.38B | -12.09 | -890.76% | ― | -0.80% | -249.48% | |
44 Neutral | AU$139.90M | -12.98 | -70.29% | ― | ― | -62.15% | |
42 Neutral | AU$45.95M | 575.00 | 0.48% | ― | 24.45% | ― | |
42 Neutral | AU$61.61M | -3.10 | -54.48% | ― | 17.24% | -20.00% |
* Healthcare Sector Average
AU:4DX
4DMedical Ltd
3.91
3.66
1464.00%
AU:CMP
Compumedics Limited
0.23
-0.06
-20.69%
AU:SOM
Somnomed Limited
0.46
-0.19
-29.23%
AU:CYC
Cyclopharm Limited
0.49
-0.51
-51.01%
AU:EMV
EMvision Medical Devices Ltd.
1.53
-0.21
-11.85%
AU:RMD
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
28.61
-9.77
-25.45%
4DMedical Ltd Corporate Events
4DMedical Issues New Shares on Option Exercise, Affirms Regulatory Compliance
Jul 10, 2026
Following the recent exercise of options under its Long Term Incentive Plan, 4DMedical has issued 1,632,125 fully paid ordinary shares, confirming compliance with key disclosure and reporting obligations under the Corporations Act. By certifying t...
4DMedical Adds 1.63 Million New Shares to ASX Quotation
Jul 10, 2026
4DMedical Ltd has applied for quotation on the ASX for 1,632,125 new ordinary fully paid shares under its existing 4DX issuer code. The shares, issued on July 10, 2026 following the exercise or conversion of existing options or other convertible s...
4DMedical Expands ASX-Quoted Share Base Through New Issuance
Jul 10, 2026
4DMedical Ltd has applied for the quotation of additional ordinary fully paid shares on the ASX, following the issue of 283,298 securities on July 3, 2026 and a further 61,778 securities on July 10, 2026. The new share quotation reflects the conve...
State Street Group Ceases to Be Substantial Holder in 4DMedical
Jul 6, 2026
State Street Corporation and several of its global asset management subsidiaries have lodged a notice that they have ceased to be substantial holders in 4DMedical Ltd. The filing, made under section 671B of the Corporations Act, indicates that the...
4DMedical Issues New Shares While Affirming Compliance and Transparency
Jul 1, 2026
4DMedical Limited, a global medtech firm listed on the ASX, specializes in AI-driven respiratory imaging solutions that transform standard scans into detailed functional lung assessments. Its SaaS-based products, including XV LVAS®, CT LVAS&#...
4DMedical Seeks ASX Quotation for Additional Ordinary Shares
Jul 1, 2026
4DMedical Ltd has applied to the ASX for quotation of 14,436 new ordinary fully paid shares under the ticker 4DX, with an issue date of 1 July 2026. The small-scale issuance, tied to a previously announced transaction, slightly increases the compa...
4DMedical Seeks ASX Quotation for Additional Ordinary Shares
Jul 1, 2026
4DMedical Ltd has applied to the ASX for quotation of 88,101 new fully paid ordinary shares under the ticker 4DX, following the issue of these securities on 1 July 2026. The additional quotation expands the company’s listed share base, signa...
4DMedical directors boost holdings as AI lung imaging strategy advances
Jun 26, 2026
4DMedical has disclosed changes in director shareholdings after Lil Bianchi and John Livingston exercised share options, converting them into ordinary shares and increasing their equity stakes in the company. The company emphasized that no directo...
4DMedical Issues New Shares Under Incentive Plan While Confirming Regulatory Compliance
Jun 26, 2026
4DMedical Limited has issued 1,677,016 fully paid ordinary shares upon the exercise of options under its Long Term Incentive Plan, expanding its share base without requiring a formal disclosure document. The company confirmed it remains compliant ...
4DMedical Lists Additional Shares on ASX Following Option Conversions
Jun 26, 2026
4DMedical has applied for quotation on the ASX of 1,677,016 new ordinary fully paid shares, issued in two tranches on June 19 and June 24, 2026. The new securities arise from the exercise of options or conversion of other convertible instruments a...
4DMedical Expands ASX-Quoted Share Base With New 4DX Issuance
Jun 26, 2026
4DMedical Ltd has applied to the ASX for quotation of new ordinary fully paid shares under its 4DX ticker. The application covers multiple small tranches totaling 520,755 shares issued on June 15, 19 and 26, 2026, following the exercise or convers...
4DMedical Plans Modest Share Issue to Support Capital Needs
Jun 26, 2026
4DMedical has notified the ASX of a proposed issue of up to 48,781 fully paid ordinary shares under a planned placement or similar capital-raising structure. The securities, which the company intends to have quoted on the exchange, are scheduled f...
4DMedical plans modest share placement to support ongoing activities
Jun 26, 2026
4DMedical has notified the ASX of a proposed issue of 88,101 fully paid ordinary shares under a placement or similar capital-raising mechanism. The new securities, to be issued on 1 July 2026, represent a modest expansion of the company’s eq...
4DMedical Wins Australian TGA Approval for CT:VQ Lung Imaging Software
Jun 25, 2026
4DMedical has secured Therapeutic Goods Administration approval for its CT:VQ ventilation-perfusion imaging software, clearing the way for commercial deployment across Australia. The product, which derives detailed lung function data from standard...
4DMedical Director Julian Sutton Increases On‑Market Shareholding
Jun 22, 2026
4DMedical has disclosed a change in the interests of director Julian Bernard Kingsley Sutton, who increased his direct holding in the company through on‑market purchases. Sutton acquired a combined 24,417 ordinary shares over two days at pri...
4DMedical launches CLEAR program to push CT:VQ into US$3bn pulmonary embolism market
Jun 1, 2026
4DMedical has launched CLEAR, a clinical evidence program designed to accelerate the adoption of its contrast-free CT:VQ technology in the acute pulmonary embolism market. By extending beyond the traditional nuclear VQ segment into the much larger...
4DMedical Plans Modest Share Issue to Support Growth
Jun 1, 2026
4DMedical Ltd has outlined plans for a new issue of ordinary fully paid shares on the ASX, signalling a modest capital raise through a placement or similar structure. The company has notified the exchange of a maximum of 56,235 new securities to b...
4DMedical buys contextflow to fast-track European lung imaging push
Jun 1, 2026
4DMedical has moved to establish a major European presence by agreeing to acquire Austrian lung imaging specialist contextflow, securing an immediate commercial and clinical platform across the region. The deal gives the company a Vienna-based tea...
4DMedical Seeks ASX Quotation for Additional Ordinary Shares
May 29, 2026
4DMedical Ltd has applied for quotation on the ASX of a small parcel of new ordinary fully paid shares, totaling 92,740 securities issued on May 25 and May 29, 2026. The additional shares, arising from the exercise or conversion of existing option...
4DMedical Secures U.S. Outpatient Rollout for CT:VQ via SimonMed Deal
May 29, 2026
4DMedical has signed a three-year commercial agreement with SimonMed Imaging, one of the largest physician-led outpatient imaging providers in the U.S., to deploy its CT:VQ and LDAf quantitative cardiopulmonary analysis tools across SimonMed’...
Citi Group Entities Cease to Be Substantial Holder in 4DMedical
May 26, 2026
Citigroup Global Markets Australia and related Citi entities have notified 4DMedical that they have ceased to be a substantial holder in the company as of 22 May 2026. The change follows a series of adjustments in relevant interests across multipl...
State Street Group Ceases to Be Substantial Holder in 4DMedical
May 4, 2026
State Street Corporation and several of its asset management subsidiaries, including State Street Global Advisors entities in Australia, Europe and the U.S., have disclosed that they have ceased to be substantial shareholders in 4DMedical Ltd. The...
4DMedical Seeks ASX Quotation for 2.16 Million New Shares
May 1, 2026
4DMedical Ltd has applied to the ASX for quotation of new ordinary fully paid shares following the conversion of options or other convertible securities. The application covers a total of 2,159,719 shares issued across three dates in April and May...
4DMedical accelerates global rollout of CT:VQ on surging scan volumes and fresh capital
Apr 30, 2026
4DMedical reported strong third-quarter momentum as it deepens penetration of leading U.S. academic medical centres with its CT:VQ lung imaging platform, adding a commercial contract with University of Chicago Medicine and a 90-day evaluation at M...
4DMedical Issues New Shares Under Long-Term Incentive Plan, Confirms Regulatory Compliance
Apr 17, 2026
4DMedical Limited has issued 162,045 fully paid ordinary shares following the exercise of options under its Long Term Incentive Plan, expanding its share capital without a formal prospectus disclosure. The company confirmed it is compliant with ke...
4DMedical Seeks ASX Quotation for Additional 1.2 Million Shares
Apr 17, 2026
4DMedical Limited has applied to the ASX for quotation of an additional 1,206,912 ordinary fully paid shares, issued on 10 April and 17 April 2026, under its ticker 4DX. The new securities arise from the exercise or conversion of existing options ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.